Abstract
Breast cancer is the most common form of cancer among women. Compared with other serum polypeptides, autoantibodies have many appealing features as biomarkers including sensitivity, stability, and easy detection. Anti-lipid autoantibodies are routinely used in the diagnosis of autoimmune diseases, but their potential for cancer diagnosis has not been explored. Dysregulation of cellular signaling in cancer cells would be expected to lead to irregular metabolism of many lipids, which could be sensed by the immune system and cause the production of autoantibodies. Discovery of anti-lipid antibodies could be used as biomarkers for early breast cancer diagnosis. We describe here a more sensitive and accurate method for lipid microarray detection using dual fluorescent labeling, and used it to examine global anti-lipid profiles in the MMTV-Neu transgenic breast cancer model. We conclude that, at the current technology, lipid microarray is not a preferred method for anti-lipid antibody detection in breast cancer animal models. Our result will help the future application of lipid microarrays in identifying anti-lipid autoantibodies in breast cancer and other human diseases.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call